Presentation is loading. Please wait.

Presentation is loading. Please wait.

Reduction of bleeding after heart operations through the prophylactic use of epsilon- aminocaproic acid  Thomas J. Vander Salm, MDa, Shubjeet Kaur, MDb,

Published byDuane Carpenter Modified over 5 years ago

Similar presentations

Presentation on theme: "Reduction of bleeding after heart operations through the prophylactic use of epsilon- aminocaproic acid  Thomas J. Vander Salm, MDa, Shubjeet Kaur, MDb,"— Presentation transcript:

1 Reduction of bleeding after heart operations through the prophylactic use of epsilon- aminocaproic acid  Thomas J. Vander Salm, MDa, Shubjeet Kaur, MDb, Robert A. Lancey, MDa, Okike N. Okike, MDa, A.Thomas Pezzella, MDa, Russell F. Stahl, MDa, Lisa Leone, BSNa, Jian-Ming Li, MDa, C.Robert Valeri, MDc, Alan D. Michelson, MDd  The Journal of Thoracic and Cardiovascular Surgery  Volume 112, Issue 4, Pages (October 1996) DOI: /S (96) Copyright © 1996 Mosby, Inc. Terms and Conditions

2 Fig. 1 Platelet surface expression of GPIb (von Willebrand factor receptor) did not change significantly during or after CPB, irrespective of whether patients received EACA (closed circles) or placebo (open circles). Platelet surface GPIb was determined at indicated time points by whole blood flow cytometry with monoclonal antibody 6D1. PRE-OP, Preoperative; HEPARIN, 5 minutes after initial heparin administration; 45 MIN CPB, 45 minutes into CPB; PROTAMINE, 5 minutes after protamine administration; 2 H POST, 2 hours after skin closure. Data are mean ± standard error of the mean; n = 13 patients for EACA and n = 10 patients for placebo. Actual preoperative values (mean flourescence ± standard error of the mean) were 33.8 ± 2.4 in EACA group and 37.0 ± 1.8 in placebo group. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

3 Fig. 2 Platelet surface expression of the GPIIb-IIIa complex (fibrinogen receptor) did not change significantly during or after CPB, irrespective of whether patients received EACA (closed circles) or placebo (open circles). Platelet surface GPIIb-IIIa complex was determined at indicated time points (see Fig. 1) by whole blood flow cytometry with monoclonal antibody 7E3. Data are mean ± standard error of the mean; n = 13 patients for EACA and n = 9 patients for placebo. Actual preoperative values (mean flourescence ± standard error of the mean) were 24.2 ± 1.5 in EACA group and 20.2 ± 0.9 in placebo group. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

4 Fig. 3 Irrespective of whether patients received EACA (closed symbols) or placebo (open symbols), platelets circulated during and after CPB with little bound fibrinogen (circles), and platelets were normally reactive to combination of ADP and epinephrine (ADP/epi), as determined by ability to bind fibrinogen to GPIIb-IIIa complex (squares). Fibrinogen binding to platelet surface GPIIb-IIIa complex was determined at indicated time points (see Fig. 1) by whole blood flow cytometry with monoclonal antibody F26. F26 binding to preoperative samples incubated with 20 mmol/L ADP and 20 mmol/L epinephrine was defined as 100%. Data are mean ± standard error of the mean; n = 12 patients for EACA and n = 7 patients for placebo. Preoperative fibrinogen binding to platelet surface GPIIb-IIIa complex in absence of agonist (mean flourescence ± standard error of the mean) was 5.8 ± 2.3 in EACA group, and 4.5 ± 1.3 in placebo group. Binding with ADP/epi agonist was 39.7 ± 8.3 in EACA group and 58.5 ± 13.9 in placebo group. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

5 Fig. 4 Platelet surface expression of P-selectin (reflecting granule secretion) was minimal whether patients received EACA (closed circles) or placebo (open circles). Platelet surface P-selectin was determined at indicated time points (see Fig. 1) by whole blood flow cytometry with monoclonal antibody S12. S12 binding to preoperative samples incubated with 2 U/ml thrombin was defined as 100%. Data are mean ± standard error of the mean; n = 12 patients for EACA and n = 9 patients for placebo. Preoperative values (mean flourescence ± standard error of the mean) were 2.7 ± 0.4 in EACA group and 2.6 ± 1.8 in placebo group. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

6 Fig. 5 Euglobulin clot lysis time, assay of fibrinolytic activity, was significantly longer, indicating less fibrinolysis in patients receiving EACA (closed circles) than in control patients (open circles). Time points as given in Fig. 1. Data are mean ± standard error of the mean; n = 14 patients for EACA and n = 11 patients for placebo. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

7 Fig. 6 Administration of EACA inhibited fibrinolysis, as evidenced by obliteration of CPB-associated increase in circulating plasma d-dimer. Time points as given in Fig. 1. Data are mean ± standard error of the mean; n = 14 patients for EACA and n = 10 patients for placebo. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

8 Fig. 7 Plasma fibrinogen levels decreased during CPB, irrespective of whether patients received EACA (closed circles) or placebo (open circles). Time points as given in Fig. 1. Data are mean ± standard error of the mean; n = 14 patients for EACA and n = 12 patients for placebo. Actual preoperative values (± standard error of the mean) were ± 33.9 mg/dl (EACA) and ± 36.6 mg/dl (placebo). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

9 Fig. 8 Plasma antiplasmin levels decreased during CPB, irrespective of whether patients received EACA (closed circles) or (open circles). Time points as given in Fig. 1. Data are mean ± standard error of the mean; n = 14 patients for EACA and n = 12 patients for placebo. Actual preoperative values (percentage of mean values in normal volunteers ± standard error of the mean) were 92.3% ± 4.5% (EACA) and 85.0% ± 2.5% (placebo). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

10 Fig. 9 Plasma antithrombin III levels decreased during CPB, irrespective of whether patients received EACA (closed circles) or placebo (open circles). Time points as given in Fig. 1. Data are mean ± standard error of the mean; n = 10 patients for EACA and n = 7 patients for placebo. Actual preoperative values (percentage of mean values in normal volunteers ± standard error of the mean) were 94.2% ± 7.1% (EACA) and 85.1% ± 3.3% (placebo). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) ) Copyright © 1996 Mosby, Inc. Terms and Conditions

Download ppt "Reduction of bleeding after heart operations through the prophylactic use of epsilon- aminocaproic acid  Thomas J. Vander Salm, MDa, Shubjeet Kaur, MDb,"

Similar presentations

Coagulation Just the basics.... Three steps Vasoconstriction Platelet plug formation Fibrin clot formation.

Coagulation Just the basics.... Three steps Vasoconstriction Platelet plug formation Fibrin clot formation.
Hydrogen Sulfide Inhibits Human Platelet Aggregation In Vitro in Part by Interfering Gap Junction Channels: Effects of ACS14, a Hydrogen Sulfide-releasing.

Hydrogen Sulfide Inhibits Human Platelet Aggregation In Vitro in Part by Interfering Gap Junction Channels: Effects of ACS14, a Hydrogen Sulfide-releasing.
Robert C. Gorman, MDa(by invitation), Nicholas P

Robert C. Gorman, MDa(by invitation), Nicholas P
Peter E. Ballmer, MDa, Walter H

Peter E. Ballmer, MDa, Walter H
Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices  Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin,

Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices  Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin,
Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits  Piet G.M. Jansen, MD,

Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits  Piet G.M. Jansen, MD,
Effects of myocardial ischemia on the release of cardiac troponin I in isolated rat hearts  Sidney Chocron, MDa, Kifah Alwan, MDa, Gerard Toubin, MDb,

Effects of myocardial ischemia on the release of cardiac troponin I in isolated rat hearts  Sidney Chocron, MDa, Kifah Alwan, MDa, Gerard Toubin, MDb,
Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations  Jari Petäjä, MDa, Kaija Peltola, MDa, Heikki Sairanen, MDa, Mauri.

Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations  Jari Petäjä, MDa, Kaija Peltola, MDa, Heikki Sairanen, MDa, Mauri.
Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy  Sally E. Webster, MB, BS, David.

Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy  Sally E. Webster, MB, BS, David.
Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog  Talia B. Spanier, MDa, Mehmet C. Oz, MDa, Oktavijan.

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog  Talia B. Spanier, MDa, Mehmet C. Oz, MDa, Oktavijan.
Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.

Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.
Yuji Hiramatsu, MDa, Nicolas Gikakis, BSEa, Harry L

Yuji Hiramatsu, MDa, Nicolas Gikakis, BSEa, Harry L
George J. Despotis, MD, Michael S. Avidan, MD, Charles W. Hogue, MD 

George J. Despotis, MD, Michael S. Avidan, MD, Charles W. Hogue, MD 
Is Aprotinin Safe to Use in a Cohort at Increased Risk for Thrombotic Events: Results From a Randomized, Prospective Trial in Off-Pump Coronary Artery.

Is Aprotinin Safe to Use in a Cohort at Increased Risk for Thrombotic Events: Results From a Randomized, Prospective Trial in Off-Pump Coronary Artery.
Jacek M. Karski, MDa, Sally J

Jacek M. Karski, MDa, Sally J
Peter E. Ballmer, MDa, Walter H

Peter E. Ballmer, MDa, Walter H
Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia  S. Krajewski,

Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia  S. Krajewski,
The effect of preoperative methylprednisolone on pulmonary function and pain after lung operations  Dennis Bigler, MDa, Torsten Jonsson, MDa, Johnny Olsen,

The effect of preoperative methylprednisolone on pulmonary function and pain after lung operations  Dennis Bigler, MDa, Torsten Jonsson, MDa, Johnny Olsen,
Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action  D.A. Payne, FRCS(Ed)a,

Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action  D.A. Payne, FRCS(Ed)a,
Tumor necrosis factor-α production in whole blood after cardiopulmonary bypass: Downregulation caused by circulating cytokine-inhibitory activities  J.

Tumor necrosis factor-α production in whole blood after cardiopulmonary bypass: Downregulation caused by circulating cytokine-inhibitory activities  J.

Similar presentations

Ads by Google